Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Tony van Werkhooven who wrote (138)	11/9/1998 1:55:00 PM
From: Ariella	Read Replies (1) \| Respond to of 1386

Dear Tony, PARS is responsible for supplying BOL with the active ingredient for Alrex & Lotemax. Everything else is BOL's responsibility. BOL is aggressively using samples to gain market share. Figures given out on the recent conference call by CFO are: 150,000 samples during June quarter 228,000 samples during Sept quarter This strategy will continue in Q4. There's no way I can think of to quantify what precripts would be without these samples, but I believe the strategy to be the correct one, as we see from the climb in prescripts since product launch. -Ariella